X4 Pharmaceuticals (XFOR) EBITDA (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported EBITDA for 10 consecutive years, with -$16.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 37.52% year-over-year to -$16.4 million; the trailing twelve-month figure through Jun 2026 stood at -$87.9 million (up 16.98% YoY), and the FY2025 full-year result was -$86.9 million, down 138.68% from the prior year.
• EBITDA advanced to -$16.4 million in Q2 2026 per XFOR's latest filing, from -$20.3 million in the prior quarter.
• Across five years, EBITDA topped out at $71.1 million in Q2 2024 and bottomed at -$37.3 million in Q1 2024.
• Historically, EBITDA has averaged -$19.7 million across 5 years, with a median of -$25.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBITDA soared 375.54% in 2024, then tumbled 136.89% in 2025.
• Over 5 years, EBITDA stood at -$25.6 million in 2022, then rose by 1.48% to -$25.2 million in 2023, then tumbled by 41.73% to -$35.7 million in 2024, then surged by 33.64% to -$23.7 million in 2025, then jumped by 30.84% to -$16.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$16.4 million, -$20.3 million, and -$23.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.